Our goal is to support your organization in building a new adaptable way of image analysis. Making your work more efficient with a great user experience.
We all do believe in the importance of healthcare improvement for people.
Your satisfaction with our products makes us work better every day.
We are building the company and products of our dreams.
Every employee has the power to make our company better.
Keen Eye team is an international and multidisciplinary team, combining years of experience in biomedical image analysis, artificial intelligence, health economics, regulatory and quality affairs in the pharmaceutical industry.
We develop these innovative tools, by working with physicians, researchers, CROs, and cytologists partners.
We share a common vision, to devise new ways to analyze biomedical images and to improve diagnosis for patients.
Sylvain Berlemont, PhD
CEO & Founder
Leandro Almeida, PhD
Senior Strategic Marketing Manager
Quality and Regulatory Manager
Soizic Laguitton, PhD
Senior Software Engineer
Chahira Miloudi, PhD
Senior Software Engineer
Office & Happiness Manager
Gaudenz Danuser, PhD
Professor & Chairman
Since July 2015 Gaudenz Danuser has been appointed as the inaugural chair of the Lyda Hill Department of Bioinformatics. He also holds the Patrick E. Haggerty Distinguished Chair in Basic Biomedical Science and is a Scholar of the Cancer Prevention Institute of Texas (CPRIT).
Before moving to UTSW, Danuser directed research laboratories at ETH Zurich (2002 – 2003), at The Scripps Research Institute in La Jolla (2003 – 2009), and at Harvard Medical School (2009 – 2014). Trained as an engineer (geodetic and electrical engineering/computer science), he entered the field of cell biology as a postdoctoral fellow in the Program for Architectural Dynamics of Living Cells at the MBL in Woods Hole.
He is co-chair of the computational and systems biology track in UTSW’s graduate school. He is also engaged extensively in the educational programs at the Marine Biological Laboratory in Woods Hole.
Currently, he is the founding director of an NIH-funded course in Computational Image Analysis in Cell and Developmental Biology. His contributions to cell biology and biophysics have been recognized by several awards and honors. Recent nominations include Recruitment Awards from the UT STARS and CPRIT programs (2012), the Charles Edward Holt Memorial Lectureship at The Massachusetts Institute of Technology (2011), a Transformative R01 Research Award from the NIH Director’s Office (2009 – 2014), and the Michael and Kate Barany Award for Young Investigators by The Biophysical Society (2009).
Philippe Tramoy joined Seventure Partners in November 2013 as Investment director within Quadrivium 1 seed fund team. He has 15 years experience as an entrepreneur and business developer in Startup and corporate. He is in charge of this fund’s investments in the Life Sciences sector.
Philippe started his career in 2000 as a project manager and business development director in the biotechnology sector at Rhodia Corporate, Rhodia Chirex and Rhodia Pharma Solutions. In 2004, he founded and managed a market and business intelligence company, CBDMT – Market & Business Intelligence.
Philippe Tramoy is graduated in biochemistry (MSc) and in immunology & genetics (MSc) from the Burgundy’s University and the Ecole Normale Supérieure in Lyon. He graduated also from IAE Paris Panthéon-Sorbonne (Master in Finance) and HEC Paris (Master in Intelligence Marketing).
Eric Peltier, MD
Medical Doctor specialized in Pathology. Awarded from Paris University of Medicine. Summa cum Laude of Saint Antoine Faculty ;
Previously, we was the founder and Director of a Private Medical Centre specialized in Pathology (Paris), the founder and President of NOVACYT (France) and CIO at NOVACYT (France-UK).
He was also associate Professor at the Hospital Antoine Béclère (Paris-France) and Medical practitioner at the Institut Gustave Roussy specialized in gynecology and cervical cancer screening
Eric holds 28 patent families (27 in cytology and one in Respiratory) representing more than 100 international patents.